SV2A and Cognitive impairment: There may be a connection with the mechanisms of action of levetiracetam since several studies using SV2A PET tracers show reduction in SV2A expression associated with several neuropsychiatric and neurodegenerative diseases that are associated with cognitive deficits (Heurling et al., 2019).